



Nicox expands Xailin™ range of ocular products

December 8, 2014.

Sophia Antipolis, France.

Nicox S.A. (NYSE Euronext Paris: COX), the international ophthalmic company, today announced that it has further expanded its branded Xailin™ range of ocular products. This now comprises six products classed as medical devices: five ocular lubricants for dry eye symptoms and one eyewash. Xailin™ is a proprietary brand marketed by Nicox in the main European markets and through Nicox's distributors in other international markets outside North America. The Xailin™ products are either preservative-free or preservative-free in the eye, thanks to the use of perborate, a 'disappearing' preservative which is converted to water and oxygen by ocular enzymes upon contact with the eye surface.

"Nicox is now offering a full range of ocular products under the Xailin brand which are specifically designed to address patients' needs," said **Philippe Masquida, Executive Vice-President, Managing Director of European & International Operations of Nicox Pharma.** *"The Xailin range has been developed based on feedback from European ophthalmologists and patients. All the Xailin products are either preservative-free or preservative-free in the eye, and most of them come in a convenient multidose packaging. We are looking forward to continuing to expand our brand with additional Xailin launches in the coming years."*

The Xailin™ range today includes the following products:

- **Xailin Wash:** sterile unidose eyewash, preservative-free.
- **Xailin Night:** multidose lubricating eye ointment shield for overnight protection of corneal tissue, preservative-free.
- **Xailin Fresh:** unidose carmellose eye drops for the relief of dry eye sensations in patients with intermittent or persistent dry eye and ocular surface damage, preservative-free.
- **Xailin HA:** multidose hyaluronic acid eye drops for alleviating symptoms of moderate to severe dry eye sensations, preservative-free in the eye.
- **Xailin Hydrate:** multidose hypromellose eye drops for the immediate relief of dry eye sensations,

preservative-free in the eye.

- **Xailin Gel:** multidose carbomer gel for the long lasting relief of dry eye sensations, preservative-free in the eye.

Nicox has established a direct commercial presence in the five major European markets, through the recruitment of specialist sales teams in the UK, Spain and Germany and through the acquisitions of Eupharmed in Italy and Doliage in France. In addition, partnerships have been established with third parties for the distribution of Nicox's products in a number of international markets outside North America.



About Nicox

Nicox (Bloomberg: COX:FP, Reuters: NCOX.PA) is an emerging international company focused on the ophthalmic market. With a heritage of innovative R&D, business development and commercial expertise, the Nicox team is building a diversified portfolio of ophthalmic products that can help people to enhance their sight. The Company has established direct commercial operations in the main European markets as well as an expanding international network of distributors.

Nicox's R&D pipeline features several near-term therapeutics, including VESNEO (latanoprostene bunod), a novel compound based on Nicox's proprietary nitric oxide (NO)-donating research platform currently in phase 3 with Bausch + Lomb for glaucoma and ocular hypertension, and AC-170 (cetirizine eye drop), which has completed phase 3 for allergic conjunctivitis. The Company is also conducting other research programs based on its NO-donating platform.

Nicox is headquartered in France and is listed on Euronext Paris (Compartment B: Mid Caps). For more information on Nicox or its products please visit www.nicox.com.

This press release contains certain forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated in the forward-looking statements.

Risks factors which are likely to have a material effect on Nicox's business are presented in: the 4th chapter of the "Document de référence, rapport financier annuel et rapport de gestion 2013" filed with the French Autorité des Marchés Financiers (AMF) on April 2nd, 2014; the "Rapport semestriel financier et d'activité au 30 juin 2014"; the 5th chapter of the "Actualisation du Document de Référence 2013" filed with the AMF on September 30, 2014 (D. 14-0271-A01); and the section B of the 'Document E' registered with the AMF on September 30, 2014 (E.14-060). All these documents are available on Nicox's website (www.nicox.com).



Contacts

Nicox
Gavin Spencer | Executive Vice President Corporate Development
Tel +33 (0)4 97 24 53 00 | communications@nicox.com

Media Relations

United Kingdom
Jonathan Birt
M +44 7860 361 746 | jonathan.birt@gmail.com

France
Caroline Courme | Communication Manager
Tel +33 (0)4 97 24 53 43 | courme@nicox.com